Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis

NCT ID: NCT01166061

Last Updated: 2011-05-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-07-31
• Study Completion Date: 2011-04-30

Brief Summary

Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans and animals, including asthma, allergic rhinitis, conjunctivitis and dermatitis. Worldwide, at least 40% of allergic patients are sensitized to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen.

ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy.

The purpose of the present study is to evaluate the safety and tolerability of multiple ascending doses of ToleroMune Grass in subjects allergic to grass.

Detailed Description

This study is designed as a randomised, double-blind, placebo-controlled study to evaluate the safety and tolerability of escalating multiple doses of ToleroMune Grass in subjects with a documented history of allergic rhinoconjunctivitis on exposure to grass. The efficacy of ToleroMune HDM will also be explored LPSR, EPSR, CPT and levels of grass specific IgE.

The study will consist of 3 study periods. In Period 1, Screening will be performed up to a maximum of 6 weeks before randomisation.

Period 2 (Treatment Period) will consist of 4 visits (Visits 3A-3D) four weeks apart. The first cohort will receive the lowest dose and successive dose groups will increasing doses of ToleroMune Grass, provided the first administration of the previous dose was safe and well tolerated.

In Period 3, 2 Post-treatment Challenge visits will take place, the first will be 2 weeks after the last administration in the Treatment Period and the second will be 17 weeks after the first administration. Follow-up will be conducted 3-10 days after the second PTC.

Conditions

Allergy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Cohort 1

Subjects to receive either active or placebo

Group Type: EXPERIMENTAL

Placebo

Intervention Type: BIOLOGICAL

Solution resembling active solution but without peptides

ToleroMune Grass

Intervention Type: BIOLOGICAL

1 x4 administrations 4 weeks apart

Cohort 2

Subjects to receive either active or placebo comparator

Group Type: EXPERIMENTAL

Placebo

Intervention Type: BIOLOGICAL

Solution resembling active solution but without peptides

ToleroMune Grass

Intervention Type: BIOLOGICAL

1 x4 administrations 4 weeks apart

Cohort 3

Subjects to receive either active or placebo comparator

Group Type: EXPERIMENTAL

Placebo

Intervention Type: BIOLOGICAL

Solution resembling active solution but without peptides

ToleroMune Grass

Intervention Type: BIOLOGICAL

1 x4 administrations 4 weeks apart

Cohort 4

Subjects to receive either active or placebo comparator

Group Type: EXPERIMENTAL

Placebo

Intervention Type: BIOLOGICAL

Solution resembling active solution but without peptides

ToleroMune Grass

Intervention Type: BIOLOGICAL

1 x4 administrations 4 weeks apart

Cohort 5

Subjects to receive either active or placebo comparator

Group Type: EXPERIMENTAL

Placebo

Intervention Type: BIOLOGICAL

Solution resembling active solution but without peptides

ToleroMune Grass

Intervention Type: BIOLOGICAL

1 x4 administrations 4 weeks apart

Interventions

Placebo

Solution resembling active solution but without peptides

Intervention Type: BIOLOGICAL

ToleroMune Grass

1 x4 administrations 4 weeks apart

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Male or female, aged 18-65 years
• Minimum 2 year history of rhinoconjunctivitis on exposure to grass
• Positive skin prick test to whole grass allergen
• LPSR to whole grass allergen 8-10 hours after intradermal injection of greater than 35mm diameter response
• Positive CPT to whole grass allergen with a score ≥4

Exclusion Criteria

• Subjects with a history of asthma
• Subjects with an FEV1 <80% of predicted
• Subjects with a rye grass specific IgE >100 kU/L
• Subjects with an acute phase skin response to whole grass allergen with a mean wheal diameter > 50 mm
• Subjects who score >1 for redness of conjunctiva or who have any watering or itchiness in the eye before administration of the CPT
• Treatment with beta-blockers, alpha-adrenoreceptor blockers, tranquillisers or psychoactive drugs
• History of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Adiga Life Sciences, Inc.

INDUSTRY

Sponsor Role: collaborator

Circassia Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Circassia Ltd

Principal Investigators

Jacques Hebert, MD

Role: PRINCIPAL_INVESTIGATOR

Centre de recherche appliquée en allergie de Quebec

Locations

Centre de Recherche Appliqué en Allergie de Québec

Québec, Quebec, Canada

Countries

Canada

Other Identifiers

TG001

Identifier Type: -

Identifier Source: org_study_id